138 related articles for article (PubMed ID: 11484952)
1. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer.
Backus HH; van Riel JM; van Groeningen CJ; Vos W; Dukers DF; Bloemena E; Wouters D; Pinedo HM; Peters GJ
Ann Oncol; 2001 Jun; 12(6):779-85. PubMed ID: 11484952
[TBL] [Abstract][Full Text] [Related]
2. 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients.
Backus HH; Dukers DF; van Groeningen CJ; Vos W; Bloemena E; Wouters D; van Riel JM; Smid K; Giaccone G; Pinedo HM; Peters GJ
Ann Oncol; 2001 Feb; 12(2):209-16. PubMed ID: 11300326
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases.
Backus HH; Van Groeningen CJ; Vos W; Dukers DF; Bloemena E; Wouters D; Pinedo HM; Peters GJ
J Clin Pathol; 2002 Mar; 55(3):206-11. PubMed ID: 11896073
[TBL] [Abstract][Full Text] [Related]
4. [Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].
Ishida H; Yamada H; Shirakawa K; Nakada H; Ohsawa T; Takeuchi I; Okada N; Yokoyama M; Inokuma S; Suzuki T; Odaka A; Hoshino T; Murata N; Hashimoto D; Itoyama S; Mori T; Matsumoto Y; Miura T
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1621-6. PubMed ID: 14619479
[TBL] [Abstract][Full Text] [Related]
5. Expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53 and p21 in metastatic liver tumor from colorectal cancer after 5-fluorouracil-based chemotherapy.
Yamagishi S; Shimada H; Ishikawa T; Fujii S; Tanaka K; Masui H; Yamaguchi S; Ichikawa Y; Togo S; Ike H
Anticancer Res; 2005; 25(2B):1237-42. PubMed ID: 15865071
[TBL] [Abstract][Full Text] [Related]
6. Expression of p53, p21/waf, bcl-2, bax, Rb and Ki67 proteins in colorectal adenocarcinomas.
Kanavaros P; Stefanaki K; Valassiadou K; Vlachonikolis J; Mavromanolakis M; Vlychou M; Kakolyris S; Gorgoulis V; Tzardi M; Georgoulias V
Med Oncol; 1999 Apr; 16(1):23-30. PubMed ID: 10382939
[TBL] [Abstract][Full Text] [Related]
7. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival.
Lenz HJ; Hayashi K; Salonga D; Danenberg KD; Danenberg PV; Metzger R; Banerjee D; Bertino JR; Groshen S; Leichman LP; Leichman CG
Clin Cancer Res; 1998 May; 4(5):1243-50. PubMed ID: 9607583
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy.
Aschele C; Debernardis D; Casazza S; Antonelli G; Tunesi G; Baldo C; Lionetto R; Maley F; Sobrero A
J Clin Oncol; 1999 Jun; 17(6):1760-70. PubMed ID: 10561213
[TBL] [Abstract][Full Text] [Related]
9. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response.
Matsuyama R; Togo S; Shimizu D; Momiyama N; Ishikawa T; Ichikawa Y; Endo I; Kunisaki C; Suzuki H; Hayasizaki Y; Shimada H
Int J Cancer; 2006 Jul; 119(2):406-13. PubMed ID: 16477629
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases.
Sturm I; Köhne CH; Wolff G; Petrowsky H; Hillebrand T; Hauptmann S; Lorenz M; Dörken B; Daniel PT
J Clin Oncol; 1999 May; 17(5):1364-74. PubMed ID: 10334520
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.
Corsi DC; Ciaparrone M; Zannoni G; Mancini M; Cassano A; Specchia M; Pozzo C; Martini M; Barone C
Eur J Cancer; 2002 Mar; 38(4):527-34. PubMed ID: 11872345
[TBL] [Abstract][Full Text] [Related]
12. A longterm follow-up study of thymidylate synthase as a predictor for survival of patients with liver tumours receiving hepatic arterial infusion chemotherapy.
Hillenbrand A; Formentini A; Staib L; Sander S; Salonga D; Danenberg K; Danenberg P; Kornmann M
Eur J Surg Oncol; 2004 May; 30(4):407-13. PubMed ID: 15063894
[TBL] [Abstract][Full Text] [Related]
13. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy.
Sulzyc-Bielicka V; Domagala P; Bielicki D; Safranow K; Domagala W
Cell Oncol (Dordr); 2014 Feb; 37(1):17-28. PubMed ID: 24277474
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer.
Gonen M; Hummer A; Zervoudakis A; Sullivan D; Fong Y; Banerjee D; Klimstra D; Cordon-Cardo C; Bertino J; Kemeny N
J Clin Oncol; 2003 Feb; 21(3):406-12. PubMed ID: 12560427
[TBL] [Abstract][Full Text] [Related]
16. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.
Aschele C; Debernardis D; Bandelloni R; Cascinu S; Catalano V; Giordani P; Barni S; Turci D; Drudi G; Lonardi S; Gallo L; Maley F; Monfardini S
Ann Oncol; 2002 Dec; 13(12):1882-92. PubMed ID: 12453856
[TBL] [Abstract][Full Text] [Related]
17. [Immunohistologic evaluation of TS, DPD, and p53 protein expression in patients with colorectal cancer having liver and pulmonary metastases].
Ishida H; Sadahiro S; Tajima T; Makuuchi H
Nihon Rinsho; 2003 Sep; 61 Suppl 7():233-6. PubMed ID: 14574888
[No Abstract] [Full Text] [Related]
18. Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data.
Chazal M; Cheradame S; Formento JL; Francoual M; Formento P; Etienne MC; François E; Richelme H; Mousseau M; Letoublon C; Pezet D; Cure H; Seitz JF; Milano G
Clin Cancer Res; 1997 Apr; 3(4):553-7. PubMed ID: 9815719
[TBL] [Abstract][Full Text] [Related]
19. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients.
Paradiso A; Simone G; Petroni S; Leone B; Vallejo C; Lacava J; Romero A; Machiavelli M; De Lena M; Allegra CJ; Johnston PG
Br J Cancer; 2000 Feb; 82(3):560-7. PubMed ID: 10682666
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
